Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3102 vs glimepiride in type 2 diabetes mellitus patients intolerant or contraindicated to metformin
2013-000301-23Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omarigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in A1C. Started Jun 2013; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-000301-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000301-23.